a Department of Oriental Medicine Biotechnology , College of Life Sciences, Kyung Hee University , Yongin , Republic of Korea.
b Department of Medicinal and Industrial Crops , Korea National College of Agriculture and Fisheries , Jeonju , Republic of Korea.
Pharm Biol. 2018 Dec;56(1):32-42. doi: 10.1080/13880209.2017.1412468.
Cynanchum wilfordii (Maximowicz) Hemsley (Apocynaceae), Arctium lappa L. var. rubescens Frivald (Asteraceae) and Dioscorea opposite Thunb (Dioscoreaceae) root extracts have been widely used as an alternative for intervening obesity.
The synergistic effect of three-herb mixture of C. wilfordii, A. lappa and D. opposita was determined on aortic and liver inflammatory responses.
CWE, ALE and DOE were prepared from the root of C. wilfordii, A. lappa and D. opposite by 70% ethanol extraction, respectively. CADE was prepared using a powder mixture of 2 CWE:1 ALE:1 DOE. C57BL/6 mice were fed an atherogenic diet combined with 10% fructose (ATHFR) in the presence of 200 mg/kg/day CWE, ALE, DOE or CADE for 8 weeks (each group, n = 6). Biochemical profiles, protein expression of vascular cell adhesion molecule-1 (VCAM-1) on the aorta and liver were determined.
CADE could significantly suppress the protein expression of VCAM-1 in both the aorta and liver (80% reduction) compared to ATHFR-fed mice. Impairment of liver function was significantly ameliorated by CADE supplement, as determined by GOT (60% reduction) and GPT (51% reduction) levels.
CADE should be considered when developing medications to suppress the vascular and liver inflammatory responses for individuals who are either non-responsive or resistant to lipid-lowering drugs.
白首乌(Cynanchum wilfordii(Maximowicz)Hemsley)、牛蒡(Arctium lappa L. var. rubescens Frivald)和山药(Dioscorea opposite Thunb)的根提取物已被广泛用作干预肥胖的替代药物。
确定白首乌、牛蒡和山药三药混合提取物(CADE)对主动脉和肝脏炎症反应的协同作用。
采用 70%乙醇分别从白首乌、牛蒡和山药的根中提取 CWE、ALE 和 DOE。CADE 采用 2 份 CWE、1 份 ALE 和 1 份 DOE 的粉末混合物制备。C57BL/6 小鼠在喂食含动脉粥样硬化饮食(ATHFR)的同时,每日给予 200mg/kg 的 CWE、ALE、DOE 或 CADE,共 8 周(每组 n=6)。测定生化谱、主动脉和肝脏中血管细胞黏附分子-1(VCAM-1)的蛋白表达。
CADE 可显著抑制 ATHFR 喂养小鼠主动脉和肝脏中 VCAM-1 的蛋白表达(降低 80%)。CADE 补充可显著改善肝功能损害,GOT(降低 60%)和 GPT(降低 51%)水平。
CADE 可用于开发抑制血管和肝脏炎症反应的药物,适用于对降脂药物无反应或耐药的个体。